Anna Tavridou PhD

Associate Professor of Pharmacology
Laboratory of Pharmacology
Faculty of Medicine, Democritus University, Greece

Top Contact Research Interests Curriculum Vitae Selected Publications Back to Lab

Contact

Telephone3025510-30530 / Fax +3025510-30530
Emailatavrid@med.duth.gr
AddressLaboratory of Pharmacology,
Faculty of Medicine,
Democritus University of Thrace,
Dragana, Alexandroupolis,
68100, Greece.

Research Interests

  • Pathophysiology of atherosclerosis: in vitro (culturing of monocytes, hepatocytes, endothelial cells) and in vivo studies (animal models).

  • Study of genetic polymorphisms involved in: a) the pathogenesis of diabetes, cardiovascular and other metabolic disease, b) response to antidiabetic, cardiovascular drugs, c) drug metabolism.

  • The role of hydrogen sulfide in cardiovascular disease.

  • Clinical studies of biomarkers in atherosclerotic disease / drug response.

  • Pathophysiology of vascular calcification: study of biochemical and genetic markers in subjects with diabetic nephropathy.

  • Pathophysiology of osteoarthritis: study of adipokines/biomarkers in human samples and effect of drugs.

  • Development of novel antiatherosclerotic, lipid-modifying, and antioxidant compounds.

Curriculum Vitae

English

Ελληνικά

Selected Publications

  • Tavridou A , Avranas A, Arzoglou P. A mathematical approach to lipolysis based on the interrelationship of physicochemical and biochemical data. Biochem Biophys Res Commun. 1992;186:746-752.
  • Tavridou A , Unwin NC, Laker MF, White M, Alberti KG. Serum concentrations of vitamins A and E in impaired glucose tolerance. Clin Chim Acta. 1997;266:129-140.
  • Bhopal R, Unwin N, White M, Yallop J, Walker L, Alberti KG, Harland J, Patel S, Ahmad N, Turner C, Watson B, Kaur D, Kulkarni A, Laker M, Tavridou A. Heterogeneity of coronary heart disease risk factors in Indian, Pakistani, Bangladeshi, and European origin populations: cross sectional study. BMJ. 1999;319:215-220.
  • Tavridou A , Laker MF. Field inversion gel electrophoresis for apolipoprotein(a) genotyping. Anal Biochem. 1999;272:282-285.
  • Tavridou A , Agius L. Phosphorylase regulates the association of glycogen synthase with a proteoglycogen substrate in hepatocytes. FEBS Lett. 2003;551:87-91.
  • Tavridou A , Unwin N, Bhopal R, Laker MF. Predictors of lipoprotein(a) levels in a European and South Asian population in the Newcastle Heart Project. Eur J Clin Invest. 2003;33:686-692.
  • Tavridou A , Manolopoulos VG. Atorvastatin and simvastatin decrease the uptake of acetylated low-density lipoprotein by human monocytes. Pharmacology. 2005;73:102-105.
  • Vryonidou A, Papatheodorou A, Tavridou A, Terzi T, Loi V, Vatalas IA, Batakis N, Phenekos C, Dionyssiou-Asteriou A. Association of hyperandrogenemic and metabolic phenotype with carotid intima-media thickness in young women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2005;90:2740-2746.
  • Tavridou A , Efthimiadis A, Efthimiadis I, Paschalidou H. Antioxidant effects of simvastatin in primary and secondary prevention of coronary heart disease. Eur J Clin Pharmacol. 2006;62:485-489.
  • Tavridou A , Kaklamanis L, Megaritis G, Kourounakis AP, Papalois A, Roukounas D, Rekka EA, Kourounakis PN, Charalambous A, Manolopoulos VG. Pharmacological characterization in vitro of EP2306 and EP2302, potent inhibitors of squalene synthase and lipid biosynthesis. Eur J Pharmacol. 2006;535:34-42.
  • Arvanitidis K, Ragia G, Iordanidou M, Kyriaki S, Xanthi A, Tavridou A, Manolopoulos VG. Genetic polymorphisms of drug-metabolizing enzymes CYP2D6, CYP2C9, CYP2C19 and CYP3A5 in the Greek population. Fundam Clin Pharmacol. 2007;21:419-426.
  • Tavridou A , Kaklamanis L, Papalois A, Kourounakis AP, Rekka EA, Kourounakis PN, Charalambous A, Manolopoulos VG. EP2306 [2-(4-biphenyl)-4-methyl-octahydro-1,4-benzoxazin-2-ol, hydrobromide], a novel squalene synthase inhibitor, reduces atherosclerosis in the cholesterol-fed rabbit. J Pharmacol Exp Ther. 2007;323:794-804.
  • Tavridou A , Kaklamanis L, Papalois A, Kourounakis AP, Rekka EA, Kourounakis PN, Charalambous A, Manolopoulos VG. Antiatherosclerotic properties of EP2302, a novel squalene synthase inhibitor, in the cholesterol-fed rabbit. J Cardiovasc Pharmacol. 2008;51:573-580.
  • Ragia G, Arvanitidis KI, Tavridou A, Manolopoulos VG. Need for reassessment of reported CYP2C19 allele frequencies in various populations in view of CYP2C19*17 discovery: the case of Greece. Pharmacogenomics. 2009;10:43-49.
  • Ragia G, Petridis I, Tavridou A, Christakidis D, Manolopoulos VG. Presence of CYP2C9*3 allele increases risk for hypoglycemia in Type 2 diabetic patients treated with sulfonylureas. Pharmacogenomics. 2009;10:1781-1787.
  • Stakos DA, Tavridou A, Margaritis D, Tziakas DN, Kotsianidis I, Chalikias GK, Tsatalas K, Bourikas G, Manolopoulos VG, Boudoulas H. Oxidised low-density lipoprotein and arterial function in beta-thalassemia major. Eur J Haematol. 2009;82:477-483.
  • Tavridou A , Arvanitidis KI, Tiptiri-Kourpeti A, Petridis I, Ragia G, Kyroglou S, Christakidis D, Manolopoulos VG. Thr54 allele of fatty-acid binding protein 2 gene is associated with obesity but not type 2 diabetes mellitus in a Caucasian population. Diabetes Res Clin Pract. 2009;84:132-137.
  • Tavridou A , Manolopoulos VG. Inhibitors of 5-lipoxygenase activating protein: WO 2008/030369. Expert Opin Ther Pat. 2009;19:1473-1476.
  • Iordanidou M, Tavridou A, Petridis I, Arvanitidis KI, Christakidis D, Vargemezis V, Manolopoulos VG. The serotonin transporter promoter polymorphism (5-HTTLPR) is associated with type 2 diabetes. Clin Chim Acta. 2010;411:167-171.
  • Manolopoulos VG, Ragia G, Tavridou A. Pharmacogenetics of coumarinic oral anticoagulants . Pharmacogenomics. 2010;11:493-496.
  • Ragia G, Nikolaidis E, Tavridou A, Arvanitidis KI, Kanoni S, Dedoussis GV, Bougioukas G, Manolopoulos VG. Endothelial nitric oxide synthase gene polymorphisms - 786T > C and 894G > T in coronary artery bypass graft surgery patients. Hum Genomics. 2010;4:375-383.
  • Tavridou A , Efthimiadis A, Efthimiadis I, Manolopoulos VG. Simvastatin-induced changes in circulating oxidized low-density lipoprotein in different types of dyslipidemia. Heart Vessels. 2010;25:288-293.
  • Tavridou A , Ragia G, Manolopoulos VG. Emerging targets for the treatment of dyslipidemia. Curr Med Chem. 2011;18(6):909-22.
  • Tavridou A , Petridis I, Vasileiadis M, Ragia G, Heliopoulos I, Vargemezis V, Manolopoulos VG. Association of VKORC1 -1639 G>A polymorphism with carotid intima-media thickness in type 2 diabetes mellitus. Diabetes Res Clin Pract . 2011;94(2):236-41.
  • Manolopoulos VG, Ragia G, Tavridou A. Pharmacogenomics of oral antidiabetic medications: current data and pharmacoepigenomic perspective. Pharmacogenomics. 2011;12(8):1161-91.
  • Iordanidou M, Paraskakis E, Tavridou A, Paschou P, Chatzimichael A, Manolopoulos VG. G894T polymorphism of eNOS gene is a predictor of response to combination of inhaled corticosteroids with long-lasting β2-agonists in asthmatic children. Pharmacogenomics. 2012;13(12):1363-72.
  • Ragia G, Tavridou A, Petridis I, Manolopoulos VG. Association of KCNJ11 E23K gene polymorphism with hypoglycemia in sulfonylurea-treated type 2 diabetic patients. Diabetes Res Clin Pract. 2012;98(1):119-24.
  • Staikos C, Ververidis A, Drosos G, Manolopoulos VG, Verettas DA, Tavridou A. The association of adipokine levels in plasma and synovial fluid with the severity of knee osteoarthritis. Rheumatology. 2013;52(6):1077-83.
  • Giannakopoulou E, Ragia G, Marousi S, Ellul J, Manolopoulos VG, Tavridou A. Association of monocyte chemoattractant protein-1 -2518A>G polymorphism with occurrence, severity, and outcome in ischemic stroke. Neurol Sci. 2013;34(8):1315-20.
  • Ragia G, Marousi S, Ellul J, Manolopoulos VG, Tavridou A. Association of functional VKORC1 promoter polymorphism with occurrence and clinical aspects of ischemic stroke in a Greek population. Dis Markers. 2013;35(6):641-6.
  • Verhoef TI, Ragia G, de Boer A, Barallon R, Kolovou G, Kolovou V, Konstantinides S, Le Cessie S, Maltezos E, van der Meer FJ, Redekop WK, Remkes M, Rosendaal FR, van Schie RM, Tavridou A, Tziakas D, Wadelius M, Manolopoulos VG, Maitland-van der Zee AH; the EU-PACT Group. A randomized trial of genotype-guided dosing of acenocoumarol and phenprocoumon. N Engl J Med. 2013;369(24):2304-12.
  • Ragia G, Tavridou A, Elens L, van Schaik RH, Manolopoulos VG. CYP2C9*2 allele increases risk for hypoglycemia in POR*1/*1 type 2 diabetic patients treated with sulfonylureas. Exp Clin Endocrinol Diabetes. 2014;122(1):60-3.
  • Giannakopoulou E, Ragia G, Kolovou V, Tavridou A, Tselepis AD, Elisaf M, Kolovou G, Manolopoulos VG. No impact of SLCO1B1 521T>C, 388A>G and 411G>A polymorphisms on response to statin therapy in the Greek population. Mol Biol Rep, 2014;41:4631-4638.
  • Lalidou F, Kolios G, Tavridou A, Drosos GI. Bone grafts as carriers for local antibiotic delivery for the treatment and prevention of bone infections. Surg Technol Int. 2014 Nov;25:239-45.

© Page maintained by George Kolios; last updated: 09/2014